What happened
Samsung Biologics updated a previously disclosed supply contract, now worth US$140M, about 46.48% of its recent annual revenue, running through Dec 2037.
For context, this single contract equals about 46.48% of the company's most recent annual revenue.
| Counterparty | Disclosed |
|---|---|
| Contract value | US$140M |
| vs. recent revenue | 46.48% |
| Through | Dec 2037 (from Aug 2018) |
| Filed | 2026-06-22, [Amended] Supply contract signed |
| Source | DART rcept 20260622800686 → open original filing |
Source: DART. Information only, not investment advice.